Does Bactrim Cover MRSA?
Yes, Bactrim (trimethoprim-sulfamethoxazole) does cover MRSA and is recommended as a first-line oral antibiotic option for community-acquired MRSA skin and soft tissue infections in outpatients. 1
Guideline-Based Recommendations
The Infectious Diseases Society of America (IDSA) explicitly lists trimethoprim-sulfamethoxazole as an A-II level recommendation for empirical coverage of community-acquired MRSA (CA-MRSA) in outpatients with skin and soft tissue infections 1. This places it on equal footing with clindamycin, tetracyclines, and linezolid for this indication.
When to Use Bactrim for MRSA:
Outpatient skin and soft tissue infections:
- Purulent cellulitis (cellulitis with drainage/exudate without drainable abscess)
- Abscesses requiring antibiotics (severe/extensive disease, systemic symptoms, immunosuppression, difficult-to-drain locations)
- Duration: 5-10 days based on clinical response 1
Important limitation: If you need coverage for both MRSA and beta-hemolytic streptococci, you must add a beta-lactam (like amoxicillin) to Bactrim, as Bactrim does NOT cover streptococci 1.
Critical Caveats Based on Infection Type
Where Bactrim Works Well:
- Skin abscesses: A 10-day course of Bactrim after drainage significantly reduces treatment failure and recurrence in MRSA infections compared to 3 days (failure rate difference 10.1%) 2
- MRSA pneumonia: Bactrim showed superior outcomes to vancomycin with lower 30-day mortality (16.7% vs 54.1%) and lower clinical failure rates (25% vs 58.3%) in a propensity-matched analysis 3
Where Bactrim Falls Short:
- Severe systemic MRSA infections with bacteremia: Bactrim failed to meet non-inferiority to vancomycin in a randomized trial, with particularly concerning results in bacteremic patients (34% mortality with Bactrim vs 18% with vancomycin, though not statistically significant) 4
- Hospitalized patients with complicated infections: Guidelines recommend IV vancomycin, linezolid, or daptomycin—not Bactrim 1
Microbiologic Activity
Bactrim demonstrates rapid bactericidal activity against MRSA in vitro, achieving >3 log₁₀ CFU/mL reduction at 24 hours—superior to most other oral agents including linezolid and clindamycin 5. This bactericidal activity is equivalent against both community-acquired and hospital-acquired MRSA strains 5.
Resistance Concerns
Resistance can emerge rapidly: In vitro studies show SXT-resistant MRSA mutants can emerge after just 8 days of exposure, with 45% of strains becoming resistant by day 14 6. This underscores the importance of:
- Using appropriate duration (not prolonged courses)
- Obtaining cultures when treating with antibiotics
- Monitoring local resistance patterns
The FDA label does NOT list MRSA as an approved indication 7, but this reflects the timing of original approval rather than current evidence and guideline recommendations.
Practical Algorithm
For uncomplicated skin abscess:
- Incision and drainage alone if simple
- Add Bactrim 1-2 DS tablets twice daily for 10 days if: systemic symptoms, extensive disease, immunocompromised, or difficult location 1, 2
For purulent cellulitis (no drainable abscess):
- Bactrim alone for 5-10 days 1
For non-purulent cellulitis:
- Start beta-lactam for streptococci
- Add Bactrim only if no response or systemic toxicity 1
For bacteremia or severe systemic infection:
For MRSA pneumonia:
- Bactrim may be superior to vancomycin, but more data needed 3